As the role of immunotherapies in treating patients with renal cell carcinoma (RCC) grows, keeping up with the pace of emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events, and educating patients to empower informed decision-making can be challenging.
This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC).
The program is being presented in two formats: a live, on-site learning workshop and an audio-guided online course.
Workshop Faculty Laura Wood, RN, MSN, OCN; Jocelyn Mohs, PharmD, BCOP; Timothy M. Kuzel, MD.
Paula Caryski, President, OSF HealthCare Saint Anthony Medical Center; Dr. Iftekhar Ahmad, Radiation Oncologist; Thelma Baker, Director of Oncology Services.
During the workshop, participants use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan. Workshop sites will report on their progress at 3 and 6 months post-participation.
We recently hosted the ACCC live workshop, "The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma." What a great experience and such a valuable benefit of our ACCC Cancer Program Membership. The three-member multidisciplinary faculty were very knowledgeable. After their educational session, we met for a collaborative quality improvement workshop with the speakers and ACCC onsite staff. They helped us develop a plan to improve our Immuno-oncology management of patients. We will use this workshop to meet our 2020 CoC standard 7.3 (Quality Improvement Initiative).
Thelma Baker, MSN, RN, OCN, NEA-BC
Director of Oncology Services
OSF HealthCare Saint Anthony Medical Center
This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with incorporating immunotherapies in the treatment of RCC in the community setting. This initiative will review the rationale for combining immunotherapies with an angiogenesis inhibitor, vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), optimal drug combinations, sequencing of therapies, patient selection criteria and monitoring and managing immune-related adverse events (irAEs) in patients with RCC.
Learn More & Register
This activity is supported by educational grants from Eisai, EMD Serono, and Pfizer.